Search results
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1...
PharmiWeb· 2 days agoAn application to the U.S. Food & Drug Administration (FDA) for approval of this additional site is scheduled for Q3 2024. As supply constraints continue for GLP-1 anti-obesity medications, ...
ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as...
PharmiWeb· 3 days ago...Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announces 48-week findings from PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomised clinical trial (RCT) investigating the 2- drug regimen Dovato...